Beacon Biosignals Upsizes Series B Financing to Over $97 Million
Summary
Beacon Biosignals announced an extension to its Series B financing, bringing the funding round to $97 million and the company's cumulative funding to over $132 million. The upsized round includes new investors JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next. Beacon develops FDA-cleared wearable EEG technology combined with AI for brain health diagnostics and precision medicine.
Why it matters
This significant funding round reflects strong investor confidence in AI-driven neurodiagnostics and at-home EEG monitoring. Beacon's platform enables objective measurement of brain function through sleep, with applications across neurology, psychiatry, and sleep medicine. The company's Waveband device directly measures brain electrical activity, supporting clinical trials and precision medicine approaches for neurological and psychiatric conditions.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial